Additionally, combining STF-083010 with the FLT3 TKI quizartinib (AC220) significantly increased malignant cell death compared to either treatment alone, indicating a promising dual-target strategy for AML therapy [57]. The gene discussed is FLT3; the disease is acute myeloid leukemia.